About Cizzle Bio, Inc.

Transforming Lung Cancer Detection through Pioneering Science

Who We Are

Cizzle Bio, Inc. stands at the forefront of biotechnological innovation, dedicated to revolutionizing the detection of lung cancer through groundbreaking diagnostic tools. With exclusive rights to detect the CIZ1B Biomarker in the USA and Canada, we are driven by a commitment to improve early cancer detection and enhance patient outcomes.

Meet the Team

Bill Behnke

Bill Behnke

CHAIRMAN & CEO

Mary Jimenez

Mary Jimenez

EXECUTIVE VICE PRESIDENT, BUSINESS DEVELOPMENT

Ron Greeno

Dr. Ron Greeno

MD, FCCP, MHM
NON-EXECUTIVE DIRECTOR

Our Journey and Technology

Born from a partnership with Cizzle Biotechnology PLC, we utilize patented technologies that have set new standards in the early detection of lung cancer. Our research and development efforts have culminated in proprietary monoclonal antibodies specific to CIZ1B, paving the way for the development of our first market-ready tests.

Leadership in Innovation

Under the leadership of Dr. Allan Syms and Professor Dawn Coverley, our team combines decades of expertise in cancer biology and cell biology, respectively. This blend of skills ensures that Cizzle Bio remains at the cutting edge of cancer diagnostics, driving innovations that promise better survival rates for patients worldwide.

The Critical Need for Early Detection

Annual Diagnoses

Over 2.2 million individuals are diagnosed with lung cancer each year globally.

0

Mortality and Prevalence

In 2020, cancer claimed 10 million lives worldwide, with lung cancer accounting for nearly 20% of these fatalities - more than any other cancer.

Late-Stage Diagnosis

Approximately 75% of lung cancer cases are diagnosed at a late stage, drastically reducing survival rates and emphasizing the need for early detection.

Survival Rates

The survival rate for lung cancer increases dramatically when diagnosed early. However, less than 20% of cases are caught in these early stages.

Screening Rates

Only 5.8% of the eligible 14.2 million people have been screened for lung cancer as of 2021, pointing to a significant gap in preventive healthcare.

The majority of lung cancer cases are diagnosed too late, with devastating consequences. Our mission is to change this narrative by providing a reliable, non-invasive, and easily accessible testing option that can dramatically improve survival rates.

Strategic Partnership for Greater Impact

Guided by Bill Behnke, a veteran healthcare executive, we actively cultivate strategic partnerships across the healthcare spectrum—from cancer centers to insurance companies. These relationships enhance the reach and effectiveness of our diagnostic solutions, ensuring they benefit a wide and diverse patient population.

Innovation at Our Core

Our commitment extends beyond traditional methods. We are developing point-of-care tests that could be as routine as checking your blood pressure, making early detection a regular part of medical care.

Learn more about the CIZ1 B Biomarker.

Educating and Empowering Communities

At Cizzle Bio, we believe in empowering individuals to take proactive steps towards managing their health. Through educational initiatives and community outreach, we raise awareness about the benefits of early lung cancer detection and encourage widespread participation in screening programs.

Our Vision for the Future

Our vision is clear: a future where lung cancer is detected early enough to be treated effectively, drastically reducing late-stage diagnoses and mortality rates. Every innovation, every partnership, and every test we develop is a step towards this future.